PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

Publication | Closed Access

DOI

239

Citations

References

2022

Year

James P Buteau, Andrew Martin, Louise Emmett, Amir Iravani, Shahneen Sandhu, Anthony M. Joshua, Roslyn J. Francis, Alison Y. Zhang, Andrew M. Scott, Sze-Ting Lee,

The Lancet Oncology

Biomarker (Medicine)Prognostic BiomarkersUrologyOncologyBiomarker AnalysisGenitourinary CancerMedicineProstatic DiseaseMolecular DiagnosticsRadiation Oncology